ASFA Classification — HDFN
Exchange transfusion for HDFN is an ASFA Category I indication — accepted as first-line therapy with strong evidence. The procedure removes sensitized neonatal RBCs, reduces bilirubin, and replaces with compatible donor blood. Maternal TPE (antenatal) is a separate Category I indication for severe fetal anemia prior to 20 weeks gestation when intrauterine transfusion is not feasible.
Disease Overview
HDFN occurs when maternal IgG alloantibodies — formed through prior pregnancy or transfusion — cross the placenta and bind to fetal red blood cell antigens. The most clinically significant antibodies are anti-D (Rh), anti-K (Kell), anti-c, anti-E, and anti-Fya. Anti-K is particularly dangerous because it suppresses erythropoiesis in addition to causing hemolysis, leading to profound fetal anemia disproportionate to the antibody titer.
The severity of HDFN ranges from mild hyperbilirubinemia (treatable with phototherapy) to severe fetal anemia, hydrops fetalis, and intrauterine death. Neonatal presentation includes jaundice within 24 hours of birth, anemia, hepatosplenomegaly, and in severe cases, kernicterus (bilirubin-induced brain damage).
Two Distinct Treatment Contexts
🍼 Neonatal Treatment: Double-Volume Exchange Transfusion (DVET)
Performed after birth for severe hyperbilirubinemia and/or anemia. Removes sensitized RBCs and bilirubin, replaces with compatible donor blood. The definitive neonatal intervention when phototherapy is insufficient.
🤰 Antenatal Treatment: Maternal TPE
Performed during pregnancy to reduce maternal antibody titers and delay/prevent fetal hydrops. Used when fetal anemia is severe and intrauterine transfusion (IUT) is not yet feasible (<20 weeks) or as an adjunct to IUT.
Neonatal Double-Volume Exchange Transfusion (DVET) Protocol
Kernicterus Prevention — Time-Critical Intervention
Kernicterus (bilirubin-induced neurological dysfunction) is irreversible. DVET must be initiated promptly when bilirubin reaches the exchange threshold. Do not delay for administrative reasons. Neonatal neurology outcomes are directly tied to the speed of bilirubin reduction.
| Parameter | Standard | Notes |
|---|---|---|
| Exchange Volume | 2 × TBV (double-volume exchange) | Neonatal TBV: 85–90 mL/kg. For 3 kg neonate: 2 × (3 × 87.5) = 525 mL exchange volume. |
| Blood Product | Reconstituted whole blood: irradiated, CMV-negative, antigen-negative pRBCs + FFP | Hematocrit of reconstituted blood: 50–55%. Must be ABO/Rh compatible with both mother and infant. |
| Access | Umbilical venous catheter (UVC) preferred in neonates; umbilical arterial catheter (UAC) for simultaneous withdrawal | Manual push-pull technique or automated using neonatal exchange transfusion kit. |
| Exchange Rate | 3–5 mL/kg per cycle; total procedure 1–2 hours | Slow, controlled exchange to prevent hemodynamic instability. Monitor HR, SpO₂, temperature continuously. |
| Bilirubin Reduction | ~50% reduction per double-volume exchange | Rebound hyperbilirubinemia expected 4–6 hours post-exchange; continue phototherapy. |
| Temperature | Blood warmed to 37°C before infusion | Hypothermia is a major risk in neonates. Use blood warmer on all infused products. |
| Electrolytes | Monitor glucose, calcium, potassium during and after procedure | Citrate in stored blood → hypocalcemia. Glucose in pRBCs → hypoglycemia rebound. Hyperkalemia in older stored blood. |
DVET Indications (AAP 2022 Guidelines)
| Clinical Scenario | DVET Threshold |
|---|---|
| Term neonate (≥38 weeks) | Total serum bilirubin (TSB) ≥25 mg/dL (428 µmol/L) OR signs of acute bilirubin encephalopathy at any level |
| Near-term (≥35–37 weeks) | TSB ≥20–22 mg/dL (adjusted for gestational age using AAP nomogram) |
| Preterm (<35 weeks) | Lower thresholds apply; consult neonatology. Generally TSB ≥10–15 mg/dL depending on gestational age and clinical status. |
| Severe anemia (Hgb <10 g/dL at birth) | Exchange transfusion regardless of bilirubin level to correct anemia and prevent cardiac failure |
| Hydrops fetalis | Immediate exchange transfusion after stabilization; may require partial exchange first to correct anemia before full DVET |
Antenatal Maternal Therapeutic Plasma Exchange
When a pregnant woman with high-titer alloantibodies (typically anti-D titer ≥1:32 or anti-K titer ≥1:8 with prior severely affected fetus) presents before 20 weeks gestation — when intrauterine transfusion (IUT) is technically difficult — maternal TPE is used to reduce antibody titers and delay the onset of severe fetal anemia.
| Parameter | Protocol | Notes |
|---|---|---|
| Indication | Antibody titer at critical level + prior severely affected fetus + gestation <20 weeks | Titres alone are insufficient; prior obstetric history is essential context. |
| Exchange Volume | 1.0–1.5 plasma volumes per session | Calculate maternal TPV using standard adult Nadler formula. |
| Replacement Fluid | 5% Albumin (primary); avoid FFP unless coagulopathy | FFP contains donor antibodies that may complicate the clinical picture. |
| Frequency | 2–3 times per week until IUT is feasible (≥20 weeks) | Monitor antibody titers weekly. Goal: reduce titer to below critical threshold. |
| Monitoring | Antibody titer, fetal MCA Doppler (peak systolic velocity) weekly | MCA PSV ≥1.5 MoM indicates fetal anemia requiring IUT regardless of titer. |
| ASFA Classification | Category I, Grade 1C (antenatal TPE for severe HDFN) | Separate from neonatal DVET classification. |
Neonatal Technical Considerations
Neonates represent the most technically demanding patient group in apheresis. Key considerations: (1) Temperature — all blood products must be warmed to 37°C; radiant warmer required throughout. (2) Electrolytes — citrate hypocalcemia, glucose dysregulation, and hyperkalemia from stored blood are all common. Monitor every 30 minutes. (3) Volume precision — the margin for error in a 3 kg neonate is <10 mL. (4) Access — umbilical catheters are standard but require confirmation of position before starting. See the Pediatric Apheresis Hub for full technical guidance.
References
All references verified February 2026. DOIs and PubMed IDs confirmed against publisher records. Links open in a new tab.
- Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice — Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38(2):77–278. doi:10.1002/jca.22043 Free Full Text — PubMed 37017433
- Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058859. doi:10.1542/peds.2022-058859 — PubMed 35927462 Open Access
- Moise KJ Jr. Management of Rhesus Alloimmunization in Pregnancy. Obstet Gynecol. 2008;112(1):164–176. doi:10.1097/AOG.0b013e31817d453c — PubMed 18591322 Abstract Only
- Zwiers C, Lindenburg ITM, Klumper FJ, de Haas M, Oepkes D, Van Kamp IL. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol. 2017;50(2):180–186. doi:10.1002/uog.17319 — PubMed 27863023
- Sawada M. Apheresis in Children. In: The Concise Manual of Apheresis Therapy. Springer; February 2026. pp. 403–419. doi:10.1007/978-981-95-4864-4_41 [Springer]